These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28679143)

  • 1. Varying Patterns of Biomarkers of Mineral and Bone Metabolism After Kidney Transplantation.
    Makówka A; Głyda M; Majewska ER; Nowicki M
    Horm Metab Res; 2017 Aug; 49(8):618-624. PubMed ID: 28679143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.
    Grethen E; Hill KM; Jones R; Cacucci BM; Gupta CE; Acton A; Considine RV; Peacock M
    J Clin Endocrinol Metab; 2012 May; 97(5):1655-62. PubMed ID: 22362819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
    Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
    Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.
    Doyon A; Fischer DC; Bayazit AK; Canpolat N; Duzova A; Sözeri B; Bacchetta J; Balat A; Büscher A; Candan C; Cakar N; Donmez O; Dusek J; Heckel M; Klaus G; Mir S; Özcelik G; Sever L; Shroff R; Vidal E; Wühl E; Gondan M; Melk A; Querfeld U; Haffner D; Schaefer F;
    PLoS One; 2015; 10(2):e0113482. PubMed ID: 25659076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
    de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
    Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol.
    Cheng Q; Wu X; Du Y; Hong W; Tang W; Li H; Chen M; Zheng S
    Clin Interv Aging; 2018; 13():2367-2374. PubMed ID: 30532527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
    Asamiya Y; Yajima A; Shimizu S; Otsubo S; Tsuchiya K; Nitta K
    Osteoporos Int; 2015 Mar; 26(3):1017-28. PubMed ID: 25366373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
    Sridharan M; Cheung J; Moore AE; Frost ML; Fraser WD; Fogelman I; Hampson G
    Calcif Tissue Int; 2010 Nov; 87(5):398-405. PubMed ID: 20838781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney transplantation restored uncoupled bone turnover in end-stage renal disease.
    Kawarazaki H; Shibagaki Y; Kido R; Nakajima I; Fuchinoue S; Ando K; Fujita T; Fukagawa M; Teraoka S; Fukumoto S
    Clin Nephrol; 2012 Jul; 78(1):10-6. PubMed ID: 22732332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.
    Fischer DC; Mischek A; Wolf S; Rahn A; Salweski B; Kundt G; Haffner D
    Ann Clin Biochem; 2012 Nov; 49(Pt 6):546-53. PubMed ID: 22984195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in vitamin D metabolite, parathyroid hormone and fibroblast growth factor-23 concentrations in sclerostin-deficient mice permit the maintenance of a high bone mass.
    Ryan ZC; Craig TA; McGee-Lawrence M; Westendorf JJ; Kumar R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():225-31. PubMed ID: 25446885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
    Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
    Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients.
    Hasparyk UG; Vigil FMB; Bartolomei VS; Nunes VM; Simões E Silva AC
    Curr Med Chem; 2022 Aug; 29(31):5230-5253. PubMed ID: 35306980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.